BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 25308752)

  • 1. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
    Sun C; Sun H; Zhang C; Tian Z
    Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
    Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
    Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
    Kalathil SG; Thanavala Y
    Cells; 2021 May; 10(6):. PubMed ID: 34071188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
    Liu P; Chen L; Zhang H
    J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells involved in tumour immune escape of hepatocellular carcinomar.
    Han C; Jiang Y; Wang Z; Wang H
    Int Immunopharmacol; 2019 Aug; 73():10-16. PubMed ID: 31078921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells in hepatitis B virus infection: a potent target for immunotherapy.
    Shabani Z; Bagheri M; Zare-Bidaki M; Hassanshahi G; Arababadi MK; Mohammadi Nejad M; Kennedy D
    Arch Virol; 2014 Jul; 159(7):1555-65. PubMed ID: 24445811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
    Yu M; Li Z
    Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
    Sung PS; Jang JW
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAC1
    Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
    Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.
    Easom NJW; Stegmann KA; Swadling L; Pallett LJ; Burton AR; Odera D; Schmidt N; Huang WC; Fusai G; Davidson B; Maini MK
    Front Immunol; 2018; 9():1009. PubMed ID: 29867983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT
    Yu L; Liu X; Wang X; Yan F; Wang P; Jiang Y; Du J; Yang Z
    Oncoimmunology; 2021; 10(1):1942673. PubMed ID: 34249476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The miR-561-5p/CX
    Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
    Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
    Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Hassouna MM; Radwan EM; Abdelsameea E; Estaphan S; Abd Elrhman HE; Abdel-Samiee M; Naguib M
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2559-2567. PubMed ID: 34452571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.